The U.S. Food and Drug Administration (FDA) granted 23andMe authorization to offer reports to customers on pharmacogenetics, indicating how customers’ genetics may influence the way they metabolize certain medications.

23andMe's new G6PD Deficiency* report provides information on whether a customer has a variant called Val68Met, which can lead to defects in an enzyme called glucose-6-phosphate dehydrogenase, or G6PD, that is associated with a form of anemia.

23andMe recently started offering customers new Genetic Health Risk reports that have received FDA authorization. Below we’ve highlighted some important features in these reports to help you get more out...

If you have an opinion about genetic testing and the best way to return those results, the U.S. Food and Drug Administration (FDA) wants to hear it at a daylong...

Starting in January with the launch of the ambitious Precision Medicine Initiative in the United States, 2015 finished with a heated debate around the appropriate use of technology that allows...

23andMe made some news today, with the launch of a new experience for customers that includes the first and only direct-to-consumer genetic service that meets U.S. FDA standards. We invested nearly...

As federal regulators listened, patients told them of their symptoms – the sleepless nights, the days with uncontrollable tremors or the little struggles simply maintaining their balance. Paul Cannon, 23andMe’s...

We all measure our age in years, but results of a study lead by researchers at Kings College in London found what may be a better measurement of age –...

By Anne Wojcicki Today, 23andMe was granted authorization by the U.S. Food and Drug Administration (FDA) to market the Bloom syndrome carrier status report. This is an important first step...

What does getting this marketing authorization mean for existing and future customers? As the first direct to consumer genetic test to complete the regulatory pathway, 23andMe’s Bloom Syndrome Carrier Status...